Clinical trials: Single Women
Hepatitis B, Chronic
A Study in Healthy Volunteers and in Participants With Chronic Hepatitis B to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7020531
This sponsor-open, investigator- and participant-blinded, multi-center study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7020531 in healthy participants and in participants with chronic…
- Trial name
- NCT02956850
- Testing
- RO7020531
- Where
- 18 sites in Bulgaria, Hong Kong and 6 more
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Healthy Volunteers, Pharmacologic Action
A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4/CYP3A5) Substrate
This study is a single-center, open-label, 3-group, fixed-sequence drug-drug interaction study to assess the effect of coadministration of multiple-dose itraconazole or diltiazem on the single-dose PK of AZD3293 and the effects…
- Trial name
- AZD3293DDI (NCT02010970)
- Testing
- Group 1 AZD3293, Group 2 AZD3293, Group 3 AZD3293
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Stress Urinary Incontinence
The European Study of Altis Single Incision Sling System for Female Stress Urinary Incontinence
This is a prospective, post-market, single arm, multicenter study comparing Baseline data to the 12 month and 36 month data in 136 female patients with Stress Urinary Incontinence
- Trial name
- EASY (NCT02049840)
- Testing
- Altis Single Incision Sling System
- Where
- 13 sites in France, Germany and 3 more
- Volunteers
- 153 people
- Sponsor
- Coloplast A/S
Renal Impairment
Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function
A study to evaluate the pharmacokinetics of CP-690,550 in subjects with mild, moderate or severe renal impairment, who do not require hemodialysis, compared to healthy controls.
- Trial name
- NCT01740362
- Testing
- CP-690,550
- Where
- 4 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Bioequivalence of Two Different Generations of Drug Product of Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers
The objective was to demonstrate the bioequivalence of capsules made from 2 different drug product batches. The reference batch was representative of the current commercial drug product and of the pivotal Phase III batches.
- Trial name
- NCT02171520
- Testing
- Dabigatran etexilate generation I, Dabigatran etexilate generation II
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Volunteers
To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects
The main purpose of the study is to demonstrate pharmacokinetic (PK) equivalence of PBP1502 to the European (EU) and American (US) Humira reference products, following a single subcutaneous (SC) dose of 40 mg in healthy…
- Trial name
- NCT05108259
- Testing
- PBP1502, EU-licensed Humira
- Where
- Spain
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Prestige Biopharma Limited
Head and Neck Cancer, Malignant Melanoma
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
The purpose of this study is to measure safety, tolerability, and preliminary antitumor efficacy of GM103 administered alone and in combination with pembrolizumab in patients with locally advanced, unresectable, refractory and/or…
- Conditions
- Head and Neck Cancer, Malignant Melanoma, Colorectal Cancer, Renal Cell Carcinoma
- Trial name
- NCT06265025
- Testing
- GM103 (Part A), GM103 (Part B), GM103 and Pembrolizumab (Part C)
- Where
- 4 sites in South Korea
- Volunteers
- 125 people
- Sponsor
- GeneMedicine Co., Ltd.
C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative
To Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients
To assess the efficacy and safety of pegcetacoplan for the prevention of recurrent C3G or primary IC-MPGN in kidney transplant recipients
- Conditions
- C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative, Glomerulonephritis (IC-MPGN), Kidney Transplantation
- Trial name
- PRESERVE (NCT07898774)
- Testing
- Pegcetacoplan
- Where
- 33 sites in Brazil, Canada and 8 more
- Volunteers
- 30 people
- Sponsor
- Swedish Orphan Biovitrum
Renal Impairment
A Study to Evaluate the Pharmacokinetics of HSK7653 in Subjects With Renal Impairment
This is an open-label, single-dose study to evaluate the pharmacokinetics, pharmacodynamics and safety of HSK7653 in subjects with mild, moderate, severe renal impairment and subjects with kidney failure compared to the matched…
- Trial name
- NCT05497297
- Testing
- HSK7653 tablets
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Healthy
A Relative Bioavailability Study of Carvedilol 12.5 mg Tablets Under Fasting Conditions
To compare the rate and extent of absorption of carvedilol from a test formulation of Carvedilol 12.5 mg Tablets versus the reference Coreg® 12.5 mg Tablets under fasting conditions.
- Trial name
- NCT00864435
- Testing
- Carvedilol 12.5 mg Tablets, single dose, Coreg® 12.5 mg Tablets , single dose
- Where
- Canada
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Actavis Inc.
Glomerulonephritis, IGA, Immunoglobulin A Nephropathy
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
A study to investigate the impact of iptacopan treatment on the underlying immunopathology in patients with IgAN by assessing changes in key clinical and molecular markers from baseline to 9 months.
- Trial name
- NCT06797518
- Testing
- Iptacopan
- Where
- 19 sites in United States, Argentina and 3 more
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Clinical Trials, Phase I as Topic
First in Human Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1214784
This study is a first in human study that will investigate the safety, tolerability and pharmacokinetics of ascending single doses of BAY1214784 using a placebo controlled, randomized, single center design.
- Trial name
- NCT02212080
- Testing
- BAY1214784
- Where
- 2 sites in Germany
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy
A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD9742 After Multiple Doses Over 14 Days
The purpose of this study is to determine the safety, tolerability and blood levels of AZD9742 after daily dosing for 14 days.
- Trial name
- NCT01064388
- Testing
- AZD9742
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Anemia, Renal Insufficiency, Chronic
A Study of Molidustat for Correction of Renal Anemia in Dialysis Subjects
The purpose of this study is to evaluate the efficacy and safety of Molidustat in dialysis subjects with renal anemia who are not treated with Erythropoiesis-Stimulating Agents (ESAs)
- Trial name
- MIYABI HD-C (NCT03351166)
- Testing
- Molidustat (BAY85-3934)
- Where
- 20 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Bayer
Enuresis
A Study to Determine if Ibuprofen in Combination With Pseudoephedrine HCl is More Effective Than Each Drug Alone in the Treatment of Nighttime Bedwetting
The purpose of the study is to determine if ibuprofen in combination with pseudoephedrine HCl in the treatment of nightime bedwetting in children is more effective than each drug alone and if the individual drugs are more…
- Trial name
- NCT00240812
- Testing
- ibuprofen; pseudoephedrine HCl
- Volunteers
- 318 people
- Sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
Parkinson's Disease
Single Ascending Dose Study of MEDI1341 in Healthy Volunteers
This is a study of single ascending intravenous doses of MEDI1341 or placebo in up to 48 healthy volunteers, aged 18 to 65 years. The study will include up to 6 planned cohorts; each cohort will comprise 8 participants.
- Trial name
- NCT03272165
- Testing
- MEDI1341
- Where
- 2 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Complication of Renal Dialysis, End Stage Renal Disease
Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes
The objective of this study is to evaluate efficacy and safety outcomes following use of the Sirolimus-eluting Collagen Implant (SeCI) in subjects undergoing surgical creation of an AV fistula for vascular access (index…
- Conditions
- Complication of Renal Dialysis, End Stage Renal Disease, End Stage Kidney Disease, ESRD
- Trial name
- ACCESS (NCT02513303)
- Testing
- Sirolimus, AV Fistula Surgery, Sirolimus-eluting Collagen Implant (SeCI)
- Where
- 4 sites in United States
- Volunteers
- 269 people
- Sponsor
- Vascular Therapies, Inc.
Healthy Volunteer
Safety, Blood Levels and Effects of AUT00201
The study medicine is a potential future treatment for schizophrenia, an illness that affects the way that people think, feel or behave.
- Trial name
- NCT04158453
- Testing
- AUT00201
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Autifony Therapeutics Limited
Bladder Cancer
RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE)
This multicenter, prospective, single-arm, phase 3 study will assess the proportion of disease-free patients, starting from administration of the first study treatment to at least 12-months after the first treatment, and up to 2…
- Trial name
- NCT02471495
- Testing
- Synergo® RITE + MMC
- Sponsor
- Medical Enterprises Europe B.V.
Renal Impairment, Hepatic Impairment
Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairment
The purpose of this study is to examine the effects of renal and hepatic impairment on TAK-272 pharmacokinetics with a single oral administration of TAK-272 in participants with renal or hepatic impairment.
- Trial name
- NCT02367872
- Testing
- TAK-272
- Where
- 4 sites in Japan
- Volunteers
- 48 people
- Sponsor
- Takeda
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.